The top drugs facing cuts under Pelosi's pricing plan

The top drugs facing cuts under Pelosi's pricing plan

Source: 
Biopharma Dive
snippet: 

The cancer drugs Revlimid, Keytruda and Opdivo, along with diabetes treatments Januvia and insulin would likely be among the medicines subject to Medicare price negotiation if a leading House proposal were to become law.